The U.S. Supreme Court on Monday said it would not review the fraud conviction of former InterMune Inc Chief Executive Scott Harkonen for a statement he made about the effectiveness of one of the company’s drugs. Harkonen was prosecuted by the U.S. Justice Department for promoting the use of Actimmune as a treatment for idiopathic pulmonary fibrosis, a lung disease, in a news release the company issued in 2002. The U.S. Food and Drug Administration had not approved the drug for that purpose.
Help employers find you! Check out all the jobs and post your resume.
